Embryonic Stem cell-based Novel Alternative Testing Strategies

akronüüm: ESNATS
algus: 2008-04-01
lõpp: 2013-09-30
 
programm: FP7 - Euroopa Liidu 7. raamprogramm
alaprogramm: HEALTH - Tervis
instrument: CP-IP - Suuremahulised integreeritud projektid
projektikonkurss: FP7-HEALTH-2007-A
projekti number: 201619
kestus kuudes: 66
partnerite arv: 32
 
lühikokkuvõte: ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an "all-in-one" test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems.
partneri jrk nr ja roll partneri nimi riik kontaktisik koduleht
1 koordinaator UNIVERSITAET ZU KOELN - UNIVERSITAETSKLINIKUM DE Jutta Landvogt http://www.kppk.de
2 partner JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION EU Raymond Crandon http://www.jrc.ec.europa.eu
3 partner UNIVERSITY OF NEWCASTLE UPON TYNE UK Amanda Gregory http://www.newcastle.ac.uk
4 partner UNIVERSITE DE GENEVE CH Pierre Spierer http://www.unige.ch
5 partner FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E.V. DE Michael Paul http://www.ifado.de
6 partner EUROPEAN CONSENSUS PLATFORM ON 3R-ALTERNATIVES TO ANIMAL EXPERIMENTATION BE Bernward Garthoff http://www.ecopa.eu
7 partner THE AUTOMATION PARTNERSHIP (CAMBRIDGE) LIMITED UK Alex Knell http://www.automationpartnership.com
8 partner Quretec OÜ EE Jaak Vilo
9 partner PROTEOSYS AG DE Bernd Matuschek http://www.proteosys.com
10 partner UNIVERSITE DE LIEGE BE Isabelle Halleux http://www.ulg.ac.be
11 partner CONSORZIO PER L'INCREMENTO ZOOTECNICO SRL IT Gerardo Marigliano http://www.ciz.it
12 partner CELLARTIS AB SE Jenny Goodwin http://www.cellartis.com
13 partner CELL CURE NEUROSCIENCES LTD IL Charles Irving
15 partner UNIVERSITAT KONSTANZ DE Margit Mosbacher http://www.uni-konstanz.de/
16 partner HEALTH PROTECTION AGENCY HPA UK Victor Knight http://www.hpa.org.uk
17 partner NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK - TNO NL John Hoebe http://www.tno.nl
18 partner THE UNIVERSITY OF EDINBURGH UK Angela Noble http://www.ed.ac.uk
19 partner VRIJE UNIVERSITEIT BRUSSEL BE Martina Follet http://www.vub.ac.be
20 partner KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE Inge Linder http://www.med.tu.muenchen.de
21 partner ARTTIC FR Eric Papon http://www.arttic.fr
22 partner UNIVERSITY COLLEGE LONDON UK Maureen Boylan http://www.ucl.ac.uk
24 partner N.V. ORGANON NL Thuijs De Boer http://www.organon.com
25 partner Medical Products Agency SE Ira Palminger Hallén http://www.mpa.se
26 partner H. LUNDBECK A/S DK Nina Ostenfeldt http://www.lundbeck.com
27 partner IN VITRO TESTING INDUSTRIAL PLATFORM ES Joan-Albert Vericat http://www.ivtip.org
28 partner BUNDESINSTITUT FUER RISIKOBEWERTUNG DE Karin Schlesier http://www.bfr.bund.de
29 partner EDINETHICS LIMITED UK Donald Malcolm Bruce http://www.edinethics.co.uk
31 partner GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER DE Ludwig Hothorn http://www.uni-hannover.de
32 partner F. HOFFMANN-LA ROCHE AG CH Nicole Clemann http://www.roche.com
33 partner AVANTEA srl IT Cesare Galli http://www.avantea.it
34 partner BRUNEL UNIVERSITY UK Teresa Waller http://www.brunel.ac.uk
35 partner EBERHARD KARLS UNIVERSITAET TUEBINGEN DE Andreas Nuessler http://www.uni-tuebingen.de